Imunon Inc - Company Profile
Powered by 
All the sales intelligence you need on Imunon Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Imunon Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Imunon Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Imunon Inc (Imunon), formerly Celsion Corp, is a clinical-stage biotechnology company focused on developing treatments that utilize the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases. The company is engaged in advancing its non-viral DNA technology across various modalities, primarily serving the biotechnology and pharmaceutical industries.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company's R&D activities focus on developing innovative immunotherapy and vaccine technologies. The company is studying IMNN-001 as an adjuvant therapy for newly diagnosed Stage III/IV ovarian cancer, in combination with chemotherapy and anti-angiogenesis compounds like bevacizumab. Additionally, Imunon is advancing its Placcine DNA vaccine technology platform, which aims to address viral mutations and improve vaccine storage and distribution. The company is also working on a next-generation COVID-19 vaccine candidate that targets multiple SARS-CoV-2 antigens using a synthetic DNA delivery system. As of December 2024, the company owned five patents related to the TheraPlas technology, with expiration dates ranging from 2025 to 2028, and has filed four new patents in 2023. For the PlaCCine technology, the company has filed three patent applications between 2021 and 2023. The company is conducting clinical studies for IMNN-001 and developing a next-generation COVID-19 vaccine. In FY2024, the company spent US$11.6 million on its R&D activities, which grew 3.1% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer